Neuro-Oncology Branch: Clinical Trials
-
Studying the biology of IDH-mutant gliomas via longitudinal observation of 2-hydroxyglutarate (2-HG) using MR spectroscopy
Open - RecruitingNCI Protocol ID NCI-19-C-0096Investigator Jing Wu, M.D., Ph.D.Share this trial: Referral ContactsContact Name Phone Number Kelly Mentges 240.760.7126 Matthew Lindsley 240.760.6534 -
Phase II Clinical Trial of Marizomib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial and Spinal Cord Ependymoma
Open - RecruitingNCI Protocol ID NCI-19-C-0011Investigator Mark R. Gilbert, M.D. -
Phase II trial evaluating Nivolumab in patients with IDH-mutant gliomas with and without hypermutator phenotype
Open - RecruitingNCI Protocol ID NCI-19-C-0006Investigator Jing Wu, M.D., Ph.D.Share this trial: Referral ContactsContact Name Phone Number Kathleen Wall 240.760.7236 Kelly Mentges 240.760.7126 -
Phase II clinical trial of sunitinib in sarcomas of the central nervous system
Open - RecruitingNCI Protocol ID NCI-18-C-0137Investigator Mark R. Gilbert, M.D.Share this trial: Referral ContactsContact Name Phone Number Kathleen Wall 240.760.7236 Sonja Crandon 240.760.6099 -
Exploring Outcomes and Risk in Patients with Rare Central Nervous System Tumors
Open - RecruitingNCI Protocol ID 17-C-N141Investigator Terri S. Armstrong, Ph.D., ANP-BC, FAAN, FAANP -
Phase II Trial of the Immune Checkpoint Inhibitor Nivolumab in Patients with Recurrent Select Rare CNS Cancers
Open - RecruitingNCI Protocol ID NCI-17-C-0102Investigator Marta Penas-Prado, M.D.Share this trial: Referral ContactsContact Name Phone Number Kathleen Wall 240.760.7236 Ukeme Ikiddeh-Barnes 240.858.7083 -
Phase II Trial of LB100, a Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma
Open - RecruitingNCI Protocol ID NCI-17-C-0037Investigator Eric C. Burton, M.D.Share this trial: Referral ContactsContact Name Phone Number Kelly Mentges 240.760.7126 Matthew Lindsley 240.760.6534 -
A randomized, double blind phase II trial of Surgery, Radiation Therapy plus Temozolomide and Pembrolizumab with and without HSPPC-96 in newly diagnosed Glioblastoma (GBM)
Open - RecruitingNCI Protocol ID NCI-17-C-0034Investigator Mark R. Gilbert, M.D.Share this trial: Referral ContactsContact Name Phone Number Matthew Lindsley 240.760.6534 Ukeme Ikiddeh-Barnes 240.858.7083 -
Phase I Trial of Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) plus Temozolomide versus Temozolomide alone in Adults with Recurrent Anaplastic Astrocytoma and Glioblastoma
Open - RecruitingNCI Protocol ID NCI-17-C-0009Investigator Jing Wu, M.D., Ph.D. -
Evaluation of the Natural History of and Specimen Banking for Patients with Tumors of the Central Nervous System
Open - RecruitingNCI Protocol ID NCI-16-C-0151Investigator Terri S. Armstrong, Ph.D., ANP-BC, FAAN, FAANP -
A Phase I-II trial of Everolimus and Sorafenib in Patients with Recurrent High-Grade Gliomas
Open - RecruitingNCI Protocol ID NCI-16-C-0011Investigator Mark R. Gilbert, M.D.Share this trial: Referral ContactsContact Name Phone Number Kelly Mentges 240.760.7126 Matthew Lindsley 240.760.6534 -
Phase II trial of Carboplatin and Bevacizumab for the Treatment of Recurrent Low-grade and Anaplastic Supratentorial, Infratentorial and Spinal Cord Ependymoma in Adults: A Multi- Center Trial
Open - RecruitingNCI Protocol ID NCI-16-C-0009Investigator Mark R. Gilbert, M.D.